Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, Anderloni G, Brunelli B, Cartocci E, Buricchi F, Tani C, Stella M, Moschioni M, Del Tordello E, Colaprico A, Savino S, Giuliani MM, Delany I, Pizza M, Costantino P, Norais N, Rappuoli R, Masignani V.

Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2714-9. doi: 10.1073/pnas.1521142113. Epub 2016 Feb 17.

2.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

3.

The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management.

Panebianco F, Mazzanti C, Tomei S, Aretini P, Franceschi S, Lessi F, Di Coscio G, Bevilacqua G, Marchetti I.

BMC Cancer. 2015 Nov 19;15:918. doi: 10.1186/s12885-015-1917-2.

4.

Association between RAD 51 rs1801320 and susceptibility to glioblastoma.

Franceschi S, Tomei S, Mazzanti CM, Lessi F, Aretini P, La Ferla M, De Gregorio V, Pasqualetti F, Zavaglia K, Bevilacqua G, Naccarato AG.

J Neurooncol. 2016 Jan;126(2):265-70. doi: 10.1007/s11060-015-1974-z. Epub 2015 Oct 28.

PMID:
26511493
5.

Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment.

Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, Yu BQ, Zhi QM, Li CL, Wang YQ, Tomei S, Cai Q, Ji J, Li JF, Chouchane L, Yu YY, Sun FZ, Xu ZH, Liu BY, Zhu ZG.

Cell Res. 2015 May;25(5):588-603. doi: 10.1038/cr.2015.51. Epub 2015 Apr 28.

6.

Obesity susceptibility loci in Qataris, a highly consanguineous Arabian population.

Tomei S, Mamtani R, Al Ali R, Elkum N, Abdulmalik M, Ismail A, Cheema S, Rouh HA, Aigha II, Hani F, Al-Samraye S, Taher Aseel M, El Emadi N, Al Mujalli A, Abdelkerim A, Youssif S, Worschech A, El Sebakhy E, Temanni R, Khanna V, Wang E, Kizhakayil D, Al-Thani AA, Al-Thani M, Lowenfels A, Marincola FM, Sheikh J, Chouchane L.

J Transl Med. 2015 Apr 13;13:119. doi: 10.1186/s12967-015-0459-3.

7.

The immune-related role of BRAF in melanoma.

Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q, Ayotte BD, Worschech A, Uccellini L, Ascierto PA, Stroncek D, Palmieri G, Chouchane L, Wang E, Marincola FM.

Mol Oncol. 2015 Jan;9(1):93-104. doi: 10.1016/j.molonc.2014.07.014. Epub 2014 Aug 6.

8.

Melanoma NOS1 expression promotes dysfunctional IFN signaling.

Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM.

J Clin Invest. 2014 May;124(5):2147-59. Epub 2014 Apr 1.

9.

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.

Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D.

Expert Opin Biol Ther. 2014 May;14(5):663-86. doi: 10.1517/14712598.2014.890586. Epub 2014 Mar 13. Review.

PMID:
24625306
10.

VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.

Lessi F, Mazzanti CM, Tomei S, Di Cristofano C, Minervini A, Menicagli M, Apollo A, Masieri L, Collecchi P, Minervini R, Carini M, Bevilacqua G.

Med Oncol. 2014 Mar;31(3):840. doi: 10.1007/s12032-014-0840-8. Epub 2014 Jan 21.

PMID:
24446253
11.

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

Pos Z, Spivey TL, Liu H, Sommariva M, Chen J, Wunderlich JR, Parisi G, Tomei S, Ayotte BD, Stroncek DF, Malek JA, Robbins PF, Rivoltini L, Maio M, Chouchane L, Wang E, Marincola FM.

J Invest Dermatol. 2014 May;134(5):1389-96. doi: 10.1038/jid.2013.495. Epub 2013 Nov 22.

12.

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, Marincola FM.

Br J Cancer. 2013 Oct 29;109(9):2412-23. doi: 10.1038/bjc.2013.557. Epub 2013 Oct 15.

13.

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.

Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, Filie A, Ascierto ML, Bedognetti D, Liu Q, Uccellini L, Chouchane L, Wang E, Marincola FM, Tomei S.

Br J Cancer. 2013 Jul 9;109(1):76-82. doi: 10.1038/bjc.2013.335. Epub 2013 Jun 27.

14.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH.

J Transl Med. 2013 Jun 12;11:145. doi: 10.1186/1479-5876-11-145.

15.

Common pathways to tumor rejection.

Wang E, Bedognetti D, Tomei S, Marincola FM.

Ann N Y Acad Sci. 2013 May;1284:75-9. doi: 10.1111/nyas.12063.

PMID:
23651198
16.

A molecular computational model improves the preoperative diagnosis of thyroid nodules.

Tomei S, Marchetti I, Zavaglia K, Lessi F, Apollo A, Aretini P, Di Coscio G, Bevilacqua G, Mazzanti C.

BMC Cancer. 2012 Sep 7;12:396. doi: 10.1186/1471-2407-12-396.

17.

IRF5 gene polymorphisms in melanoma.

Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM.

J Transl Med. 2012 Aug 21;10:170. doi: 10.1186/1479-5876-10-170.

18.

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.

Tomei S, Adams S, Uccellini L, Bedognetti D, De Giorgi V, Erdenebileg N, Ascierto ML, Reinboth J, Liu Q, Bevilacqua G, Wang E, Mazzanti C, Marincola FM.

Med Oncol. 2012 Dec;29(5):3456-61. doi: 10.1007/s12032-012-0255-3. Epub 2012 May 22.

19.

Reflections upon human cancer immune responsiveness to T cell-based therapy.

Wang E, Tomei S, Marincola FM.

Cancer Immunol Immunother. 2012 Jun;61(6):761-70. doi: 10.1007/s00262-012-1274-9. Epub 2012 May 11. Review.

20.

The stable traits of melanoma genetics: an alternate approach to target discovery.

Spivey TL, De Giorgi V, Zhao Y, Bedognetti D, Pos Z, Liu Q, Tomei S, Ascierto ML, Uccellini L, Reinboth J, Chouchane L, Stroncek DF, Wang E, Marincola FM.

BMC Genomics. 2012 Apr 26;13:156. doi: 10.1186/1471-2164-13-156.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk